🇺🇸 FDA

Company profile · Sponsor

Partner

Partner Therapeutics Limited

E767397 · EMA pharma GB
Pipeline
10
Drugs
0
Patents
0

Quick answer

Partner (E767397) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E767397
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (10)

Search pipeline →

  1. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  2. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  3. PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.

    Partner

    Stage IIB-IIIB (N2) resectable non small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. Adagrasib

    Partner

    Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2

    phase 2 small molecule active

    1 trial

  5. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Partner

    NSCLC, synchronous oligo-metastatic

    phase 2 small molecule active

    1 trial

  6. IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Partner

    Extensive-disease small cell lung cancer and high SLFN11-expression

    phase 2 small molecule active

    1 trial

  7. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  8. MCLA-128

    Partner

    Solid Tumors

    phase 2 small molecule active

    1 trial

  9. Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

    Partner

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  10. Tarlatamab, Tarlatamab

    Partner

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Partner?

Partner (E767397) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 10 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Partner sponsor?

We track 10 ClinicalTrials.gov-linked programs for Partner, including IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules and 9 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Partner company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.